NCT07175038View on ClinicalTrials.gov

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2029

Conditions
Pulmonary Arterial Hypertension (PAH)Pulmonary Hypertension, Interstitial Lung Disease
Interventions
DRUG

ROC-101

Oral, daily administered Rho kinase inhibitor

Sponsors

Lead Sponsor

AllRock Bio, Inc.
All Listed Sponsors
lead

AllRock Bio, Inc.

INDUSTRY

NCT07175038 - A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY) | Biotech Hunter | Biotech Hunter